Your browser doesn't support javascript.
loading
Current perspectives on the management of refractory or relapsed classic hodgkin lymphoma in brazil: Balancing efficacy, safety, and tolerability.
Xavier, Flávia Dias; Farias, Danielle Leão Cordeiro de; Neto, Abrahão Elias Hallack; Ribeiro, Glaciano Nogueira; Araujo, Marco Aurelio Salvino de; Carneiro, Thiago Xavier; Baiocchi, Otavio Cesar Carvalho Guimarães.
Afiliação
  • Xavier FD; Hospital Universitário de Brasília-Universidade de Brasília/Ebserh, Brasília, DF, Brazil.
  • Farias DLC; Hospital DF Star, Oncologia D'Or, Rede D'Or, Brasília, DF, Brazil.
  • Neto AEH; Hospital A Beneficência Portuguesa de São Paulo, São Paulo, SP, Brazil.
  • Ribeiro GN; Universidade Federal de Juiz de Fora, Juiz de Fora, MG, Brazil.
  • Araujo MAS; Clínica Hematológica/Grupo Oncoclinicas, Belo Horizonte, MG, Brazil.
  • Carneiro TX; Universidade Federal da Bahia, Salvador, BA, Brazil.
  • Baiocchi OCCG; Instituto D'Or de Pesquisa e Ensino, IDOR, BA, Brazil.
Oncotarget ; 14: 977-994, 2023 Dec 12.
Article em En | MEDLINE | ID: mdl-38085126
Classic Hodgkin lymphoma (CHL), which accounts for 90-95% of all cases of Hodgkin lymphoma, is the most frequent cancer in adolescents and the most frequent lymphoma in adolescents and young adults. Despite progressive improvements over past decades and the general sensitivity of CHL to frontline chemotherapy, approximately 10-15% of patients have refractory disease that either does not respond to such therapy or progresses after an initial partial response. In patients with refractory or relapsed disease, standard treatment until recently consisted mainly of salvage chemotherapy, in many cases followed by high-dose chemotherapy and autologous stem-cell transplantation. However, improved understanding of the pathobiology of CHL, coupled with the introduction of novel agents, has markedly changed the treatment landscape in the past decade. Although refractory or relapsed CHL continues to be challenging, the therapeutic landscape is undergoing profound changes brought about by novel agents, particularly brentuximab vedotin and immunotherapy. In this review, we discuss the most salient treatment options for adult patients with refractory or relapsed CHL, with a special focus on the Brazilian healthcare setting, which is constrained by inherent characteristics of this system. In the attempt to balance efficacy, safety and tolerability, practicing physicians must rely on clinical trials and on results from real-world studies, and use their own point of view and experience, as well as patient characteristics and previous therapy, to make treatment decisions for refractory or relapsed CHL.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Imunoconjugados / Transplante de Células-Tronco Hematopoéticas Limite: Adolescent / Adult / Humans País/Região como assunto: America do sul / Brasil Idioma: En Revista: Oncotarget Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Brasil País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Imunoconjugados / Transplante de Células-Tronco Hematopoéticas Limite: Adolescent / Adult / Humans País/Região como assunto: America do sul / Brasil Idioma: En Revista: Oncotarget Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Brasil País de publicação: Estados Unidos